Abstract 445P
Background
Nasopharyngeal cancer (NPC) is notably prevalent in Southeast Asia, including Hong Kong. The survival rate of NPC patients has improved over the past decade. However, the emergence of various late radiation side effects during survivorship remains a concern. While the clinician-reported incidence of symptoms has been reported, a comprehensive assessment of self-reported symptoms is still lacking. This study aims to examine the subjective symptom burden, quality of life, and unmet needs among local NPC survivors.
Methods
A single-centre cross-sectional survey was conducted at a local public hospital, including 200 NPC survivors who had completed radiation therapy (RT) with or without chemotherapy for three to 120 months. We employed the Chinese version of three questionnaires: M. D. Anderson Symptom Inventory - Head & Neck Module (MDASI-HN), Functional Assessment of Cancer Therapy - Head & Neck (FACT-HN), and Cancer Survivors’ Unmet Needs Measure (CaSUN).
Results
Survivors experienced, on average, more than four moderate to severe symptoms (Mean [M] ± SD = 4.84±4.99), with no association found with post-RT time (p = 0.443). The top five severe symptoms were dry mouth (M±SD = 5.47±2.90), mucus problem (M±SD = 4.27±3.17), dysphagia (M±SD = 3.38±3.03), teeth/gum problems (M±SD = 2.98±3.17), and poor memory (M±SD = 2.94±2.63). The mean scores of the top five symptoms were used to represent the symptom burden, which was negatively associated with the physical (F(1,198) = 139.783, p < 0.001, R2 = 0.414), emotional (F(2,197) = 38.303, p < 0.001, R2 = 0.280), additional concerns (F(1,198) = 85.993, p < 0.001, R2 = 0.303) subscales, and the total scores (F(2,197) = 33.083, p < 0.001, R2 = 0.251) of the FACT-HN. The unmet need for symptom management by CaSUN was positively associated with symptom burden (OR = 1.379, 95% CI [1.185, 1.604], p < 0.001), while negatively associated with post-RT time (OR = 0.981, 95% CI [0.972, 0.991], p < 0.001).
Conclusions
NPC survivors suffer from symptoms irrespective of the time elapsed post-RT. The observed varying unmet need for symptom management necessitates further exploration into supportive care for cancer survivors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
613P - Differences in the interactions with pharmaceutical companies between medical oncologists and infectious diseases physicians
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
614P - The role of PD-L1 expression in prognosis of osteosarcoma patients: A systematic review and meta-analysis
Presenter: Alexander Purnomo
Session: Poster Display
Resources:
Abstract
615P - Pulmonary resectable metastases of osteosarcoma with apatinib and chemotherapy (PROACH): An open-label, single-arm phase II clinical trial
Presenter: Qiyuan Bao
Session: Poster Display
Resources:
Abstract
616P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Presenter: Paula Franco
Session: Poster Display
Resources:
Abstract
617P - The risk of acute myeloid leukaemia in patients with Ewing's sarcoma and trend analysis: A SEER-based study 2000-2020
Presenter: Mohamed Abdalla
Session: Poster Display
Resources:
Abstract
618P - Adult renal Ewing’s sarcoma/primitive neuroectodermal tumor: A 20-year retrospective review of molecular histopathological profiles, and clinical outcomes
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
619P - Single-cell and bulk RNA-seq analyses decode the renal microenvironment induced by polystyrene microplastics in mice receiving high-fat diet
Presenter: Wangrui Liu
Session: Poster Display
Resources:
Abstract
620P - A unique circulating microRNA pairs signature serves as a superior tool for early diagnosis of pan-cancer
Presenter: Dongyu Li
Session: Poster Display
Resources:
Abstract
621P - Effective identification of primary liver cancer from cirrhosis or chronic hepatitis virus infection using eight methylated plasma DNA markers: Marker discovery, phase I pilot, and phase II clinical validation
Presenter: Tian Yang
Session: Poster Display
Resources:
Abstract
622P - A prognostic and immune infiltration analysis of CCL26 in pan-cancer
Presenter: Mengyue Li
Session: Poster Display
Resources:
Abstract